Summary.-The antigen specific cell mediated cytotoxicity of MSV immune spleen lymphocytes to 51Cr labelled murine lymphoma cells was wholly abolished by pretreatment of the spleen cells with anti-0 antibody and complement. Early during the immune response to MSV the cytotoxic activity was inhibited by incubation of immune lymphocytes with "late progressor" or "early regressor" serum.
In adult animals, tumours generally develop at the site of injection within 5-8 days and reach a maximum size in about 10-15 days (Fefer et al., 1968) .
Most tumours subsequently regress, the regression usually being complete by 25 days (Fefer et al., 1968; Lamon et al., 1972) .
Several workers have demonstrated syngeneic cell mediated cytotoxicity (CMC) in this system (Hellstrom and Hellstrom, 1969; Lamon et al., 1973; Leclerc et al., 1973; Plata and Levy, 1974) . CMC by both T and non-T lymphocytes has been detected in a microcytotoxicity (MCA) assay (Lamon et al., 1973) . Cytotoxic T cells were found immediately before tumour development and during regression, but disappeared after 30 days. The cytotoxic non-T cell population, however, although also present before the tumour had appeared and during regression, was most active at 30 days and was still active at Day 60. Neither T nor non-T cells were active at the time of peak tumour size (Lamon et al., 1973) .
In contrast, the peak cytolytic activity in a chromium release test (CRT), which, as in allogeneic systems, measures exclusively T cell cytotoxicity was found at about Day 15 (Cerottini, Nordin and Brunner, 1970; Leclerc et al., 1973) . The differences in cytotoxic T cell kinetics in CRT and MCA have been confirmed using the same immune lymphoid cell preparations in both assays (Plata and Levy, 1974) . In a similar rat lymphoma system, the cytotoxicity of immune T cells can be increased by incubation in vitro (de Landazuri and Herberman, 1972) . Since (Lamon et al., 1973) , this effect may be mediated by Fc receptor bearing non-immune cells in the presence of sensitizing antibody (Maclennan, Loewi and Harding, 1970) . Immune T lymphocytes, however, are specifically sensitized to tumour associated antigens in MSV regressor mice (Gorczynski, 1974a; Knight and Gorezynski, 1975) , and these immune T cells can aid in tumour rejection (Gorczynski, 1974b; Gorczynski and Norbury, 1974) .
Of equal interest to the question of the nature of the immunologically reactive cells in tumour bearing (and regressor) mice, is the question of the role of specific and nonspecific immunosuppressing factors in these animals. Earlier studies in the MSV system suggested that progressor animals contained factors in the serum able to block the cytotoxicity in vitro of progressor and regressor lymphocytes (Hellstrom and Hellstrom, 1969) . Evidence was presented that such blocking factors in tumour bearer animals were antigen-antibody complexes (Sjogren et al., 1971) . Using a more quantitative 51Cr cytotoxicity assay, Leclerc et al. (1973) were unable to reproduce these findings. Moreover, it has recently become apparent that progressor animals contain a cell population able to block the in vitro activity of T lymphocytes in a nonspecific manner (Gorczynski, 1974c) . It has been suggested that this type of effect could still be mediated via antigen-antibody complexes and evidence to support this contention has recently been presented . There is at present only circumstantial evidence that specific and nonspecific blocking factors analysed in vitro have any relevance to the in vivo tumour situation.
One other area which we at present know little about is the role of virus coded antigens in the immune response to virally induced tumours. There is now evidence that both virus coded antigens (e.g. viral envelope antigen, VEA) and a virus induced antigen with viral group specificity exist as tumour associated surface antigens (TASA) in the avian RNA tumour virus situation (Gelderblom, Bauer and Graf, 1972) and in the MSV tumour situation (Eckner and Steeves, 1972; Aoki et al., 1972; Yoshiki et al., 1974) . Lymphocytes reactive to the two avian TASA (Kurth and Bauer, 1972) have been detected by microcytotoxicity tests. In a rat MLV-G induced lymphoma system, cytotoxic antibody is directed principally, and immune lymphocytes partially, against the internal virion antigen, p30 (Shellam and Knight, 1974; Knight et al., 1974) . In the murine MSV system there is evidence that p30 is the main tumour rejection antigen . We have developed a 51Cr cytotoxicity assay for lymphoid cells from MSV inoculated mice with a view to answering several questions of fundamental importance. We wished to examine the kinetics of the development of cell mediated cytotoxicity, the cell(s) responsible for this lysis and the relationship between these cell types and those described using alternative assays for immunity in this system. Finally, we have examined the ability of purified viral antigens and serum taken from mice at different times post MSV inoculation to block direct cell mediated cytotoxicity caused by different populations of effector cells.
MATERIALS AND METHODS
Mice. Male Balb/c and C57BI/Blue (hereafter referred to as C57B1 for clarity) were obtained from the ICRF breeding unit at Mill Hill.
Turmours and in vivo sensitization.-Sarcomata were induced in 30-day old Balb/c mice by injection in the thigh of 0 1 ml crude MSV tumour homogenate as described earlier (Gorczynski, 1974a (Miller and Phillips, 1969) . Sterile glass chambers, either 11-0 cm or 16-8 cm in diameter (Aimer Glass Co., London, England) were used according to the number of cells to be separated. The initial cell band was loaded in 0-30% BSA in PBS, the total cell concentration (viable and non-viable) being no greater than 10 X 106/ml. Antisera and treatment of cells with antisera. The preparation of 2 rabbit antisera, anti-mouse brain associated theta (anti-Br-0) and anti-immunoglobulin (anti-Ig) are described in detail elsewhere (Gorezynski, 1974b) . Also in this report are data confirming the specificity of these 2 antisera, in the presence of guinea-pig complement, for cytotoxicity to murine T or B lymphocytes respectively. Thus, the anti-Br-6 killed 70% of murine peripheral lymph node cells, 100% of mouse thymocytes and removed the PHA responsive cells (but not the LPS responsive cells) from a mouse spleen cell suspension. In addition, the anti-Br-0 removed the T helper cell activity for an anti-sheep erythrocyte (SRBC) antibody response while not affecting the B cell response to a thymus independent antigen (polymerized flagellin, POL). In contrast, the anti-Jg did not kill appreciable numbers of thymocytes or remove the PHA responsive cells from a mouse spleen cell suspension, or affect T helper cells for an anti-SRBC response. However, the anti-Ig did remove LPS responsive cells from a spleen cell suspension and did remove B cells responding to both thymus dependent (SRBC) and thymus independent (POL) antigens.
Cells to be treated with either antiserum were suspended in 0-1% BSA in PBS, with the final concentration of anti-serum present being 1/15 (anti-Br-0) or 1/10 (anti-Ig). The cells were incubated for 90 min at 4°C, washed (200 g for 5 min at 4°C), resuspended in either DF10 or guinea-pig complement (diluted 1/10 in DF10), and ineubated for a further 45 min at 37°C. The cells were then rewashed as above and used as described in the text.
Cytotoxicity assay.-5 to 10 x 106 SDLC cells were radiolabelled in 1 ml DF10 containing 100,uCi 51Cr (as sodium chromate, Radiochemical Centre, Amersham, England) for 60 min at 37°C in 10% CO2 in air. The cells were washed 4 times in 25 ml DF1O (at room temperature). They were then resuspended in 25 ml DF10 and incubated at 37°C in 10% CO2 in air for a further 3-4 h before use as targets in the cytotoxic test. We found that this preincubation of the labelled target cells dramatically reduced their spontaneous release during the assay period and allowed the latter to be performed for 15 h with acceptably low spontaneous 51Cr release. Immediately before use in the assay the cells were washed once as above and suspended to a concentration of 5 Rabbit anti-mouse immunoglobulin columns (anti-MIg columns).-Rabbit anti-MIg columns were prepared as described previously (Kilburn, Smith and Gorczynski, 1974) . The maximum capacity of the column used was found experimentally to be 2 mg mouse immunoglobulin. Mouse serum was absorbed on these columns at pH 7 0 in PBS, 0 3 ml serum being washed on to the column with 1 ml PBS. The (Cerottini et al., 1970) this 5'Cr assay shows a semi-logarithmic relationship between percent specific lysis and effector : target cell ratio. As an example, the upper panel of Fig. 1 (Leclerc et al., 1973) , two major peaks of activity were observed; the first some 10-12 days post MSV injection (when the tumour was in its progressive phase of growth) and a second broader peak, 22-30 days post MSV, after the tumour had regressed. This biphasic response closely parallels the kinetics of T cell cytotoxicity measured in the MCA assay (Lamon et al., 1972) . In other assays for T cell immunity, however, (lymphocyte transformation and macrophage migration inhibition) the decline in activity occurred between days 9-14, when the tumour was growing progressively (Gorczynski, 1 974a, c) .
These findings will be discussed in detail later. of polyoma virus transformed fibroblasts, at which time effector lymphocytes specific to polyoma tumour antigens exist (as defined by a macrophage migration inhibition assay; Gorczynski, 1974a taneously cytotoxic towards 51Cr-spleen cells of C57B1 or CBA mice. As defined by these tests, the cytotoxicity measured is antigen specific. Further data in support of this contention will be mentioned later.
In order to investigate the nature of the MSV immune cytotoxic effector cells at different times post MSV infection, we have used the ability of previously described anti-Br-O and anti-Ig antisera to kill respectively murine T or B lymphocytes (Gorczynski, 1974b) . Spleen cells taken from pools of 4 mice at various times post MSV infection were left untreated or were treated with either antiserum with guinea-pig complement, or with complement alone. Each cell population was tested at various ratios for specific cytotoxicity to 51Cr-SDLC cells. The data from this experiment, showing the cytotoxicity at one ratio (100: 1), are shown in Table I . At all times post MSV infection the cytotoxicity is mediated by T lymphocytes (anti-Br-O sensitive cells). The increase in activity after treatment with anti-Ig is presumably due to the increased percentage of T cells in these preparations (since equivalent numbers of viable cells after treatment were tested). These results would concur with previously reported studies on the effector cells in other tests of immunity (Gorczynski, 1 974a, b, c) and with the data of Herberman et al. (1973) using a 51Cr cytotoxicity test in the MSV system. They are in marked contrast with those of Lamon et al. (1973) , who have evidence for a change in the nature of the effector cells as a function of time post MSV infection. (Gorczynski, 1974a, b, c) (Gorczynski, 1974c ) have no effect on cytotoxic activity, a point already discussed elsewhere In an earlier report we compared the activity of various sera taken from mice at different times post MSV inoculation for their ability to cause specific inhibition of enhanced DNA synthesis in MSV immune cells mediated by a tumour associated cell surface antigen showing viral group specificity, C-Vgs . In Fig. 4 we show a comparison of the ability of these sera to block cytotoxicity to 51Cr-SDLC or 5'Cr-C57BI spleen cells.
Ten Balb/c mice were injected intraperitoneally with 5 x 107 C57B1 spleen cells and 10 days later they were inoculated with MSV in the flank. Ten days after injection with MSV the mice were sacrificed, the spleen cells pooled and the cells tested at various concentrations with or without a constant concentration (2%) of serum from the mice given MSV at the times shown (Fig. 4) . For each cell concentration (in the presence or absence of serum) the cytotoxicity to both 51Cr-labelled SDLC and C57B1 spleen cells was tested. Once again, because of the high level of background release with these latter target cells we used only an 8-h assay for this exp3riment.
The background release as a percentage of detergent release with SDLC and C57B1 cells for this period was 13 ± 0*7 and 27 i 1-7 respectively. The data are shown as a percent blocking (of specific lysis in the absence of MSV sera) by 2% MSV sera using a 250: 1 effector: target ratio. The upper panel of this figure shows the effect of varying the effector: target cell ratio on the blocking seen using a given serum (from mice inoculated with MSV 18 days beforehand).
The data of this figure show some interesting features. Firstly, the ability of sera to inhibit the cytotoxic response does not correlate well with the peak (Gorczynski, 1974c The effector cells used in the test were from mice inoculated with 50 x 106 C57B1 spleen cells 20 (lays earlier followed by MSV 10 days later. The upper panel of the figure represents blocking with various effector cell numbers and a given serum (18 days post MSV). All sera in general showed similar effects, with the exception of early MSV sera (see figure) which often showed enhanced cytotoxicity. This is described in detail elsewhere (Gorczynski, in preparation) . The lower panel shows the blocking phenomenon obtained with different sera and a constant effector target ratio (250 : 1). In the absence of any sera the percent specific cytotoxicity to SDLC ancl C57BI spleen cells at this effector : target ratio was 32 ± 2 -2 and 46 + 3 -i respectively. serum (7-11 days post MSV) seems to enhance the cytotoxic response (see lower panel of Fig. 4) . This effect, which may be a reflection of antibody mediated cellular cytotoxicity, will be discussed in a forthcoming communication.
Our earlier work showed that the blocking activity seen with 20-day MSV serum was partially removed by preabsorption of the serum on an anti-MIG column (see Materials and Methods). The data of . Spleen cells were pooled from 4 mice given MSV 11 days earlier and the percent specific lysis seen with these cells (and 51Cr-SDLC cells) was compared in the presence or absence of various concentrations of the antigens (and serum) under test. The data shown in Table II represent the blocking of cytotoxicity at a 100: 1 effector: target ratio in MSV spleen cells (from mice given MSV 11 days earlier). In addition, the incubation medium contained the various factors shown, whose blocking activity was under test, at two (lifferent concentrations (see Table II ). The preparation of all these materials is (described in detail in the text and elsewhere (Knight and Gorezynski, 1975) . Twenty-day MSV serum was used before and after absorption on an anti-MIg column. In this case all column treated materials (i.e. effluent, absorbed and acid-eluted, and the recombined fractions) were concentrated by vacuum dialysis to their equivalent starting volume prior to test. While cells responsive to whole MSV(M) and VEA exist at this time after sensitization (Knight and Gorczynski, 1974) , it is clear from Table II that the cytotoxicity to 5'Cr-labelled SDLC cells is not blocked by these purified viral antigens nor by the purified Gross virus pseudotype of MSV(M), MSV(G). However, MSV(M) and MSV(G), disrupted by the detergent Triton X-100, are roughly equipotent inhibitors of CMC, suggesting that cytotoxic lymphocytes recognize internal group specific viral antigens on the target cell surface. The major such antigen, p30, purified from MSV(M), inhibits CMC although we have not tested higher concentrations of this antigen to determine whether cytotoxicity could be totally inhibited. A much more potent inhibitor was extracted by papain digestion from SDLC cells themselves (C-Vgs) . These data agree well with our earlier findings investigating the relative importance of sensitization to the respective MSV tumour associated antigens for in vivo tumour regression . Moreover, we were able to repeat the findings of an earlier report that the blocking activity in 20-day MSV serum could be absorbed on (and eluted from) an antiMIg column . With the data showing that blocking with MSV sera was enhanced when column effluent and acid eluted material were recombined (see Table II ), we feel that blocking in these sera is probably mediated by antigen and/or antigenantibody complexes.
Blocking of different populations of effector cells by 20-day MSV sera
Having described here (Fig. 3 ) and elsewhere (Knight and Gorczynski, 1974) the heterogeneity of effector cells to MSV-TAA, we were interested in the ability of these different populations to be blocked by MSV blocking sera. Ac- cordingly we performed two types of experiment.
In the first we took cells from animals of different times post MSV infection and investigated the cytotoxicity of these cells at various effector cell: target cell ratios in the presence or absence of a standard concentration of 20-day MSV serum (2%) or C-Vgs (150 ,ug/ml). The blocking seen with that ratio of cells giving the same percent specific cytotoxicity in the absence of serum (a function of different effector: target cell ratios for the different populations) was then determined. These data, together with the respective ratios giving the same cytotoxicity (30%) in the unblocked population, are indicated in Table III . Whereas C-Vgs apparently blocks effector cells from mice at all times post MSV infection, 20-day MSV serum was less able to block the cytotoxicity of effector cells later in the response.
In a second experiment, we fractionated cells by velocity sedimentation from animals given MSV 12 days earlier and tested the fractions at different ratios in the presence or absence of a standard concentration of 20-day MSV serum (2%) or C-Vgs (150 ,ug/ml). 10 x 108 spleen cells from mice given MSV 11 days earlier were sedimented for 4 h at 40C and fractions sedimenting with the velocities shown in Fig. 5 were pooled and centrifuged as before. The recovered cells were resuspended in DF10, recounted, and cultured with 5 x 104 51Cr-SDLC cells at various effector: target ratios, in the presence and absence of C-Vgs (150 ,ag/ml) or 20-day MSV serum (2%). After 15 h the supernatants were harvested and the percent specific 51Cr release from the various fractions and an unfractionated control sample were calculated as before. The percent blocking of this activity was calculated from that ratio of cells which, from all fractions, gave 30% specific release in the absence of blocking factors. Once again this is a valid comparison provided (as here) the titration curves from the respective fractions are parallel.
The data of Fig. 5 show a good correlation between the ability of both C-Vgs and 20-day MSV serum to block the cytotoxicity from different subpopulations of lymphocytes. Nevertheless, the most interesting feature is the demonstration that a population of cytotoxic T lymphocytes (see Table I ) exists which is not appreciably blocked by either serum or C-Vgs. As in Table III , the inhibition by serum, where demonstrable, was generally less than that mediated by C-Vgs. Since we have shown that at least some of the serum mediated inhibition is due to factors which bind to an anti-immunoglobulin column , this suggests that antibody (perhaps complexes with antigen) is a less potent blocking reagent than free TAA. Alternatively, the differences may be caused by different concentrations of blocking materials in these preparations.
In view of the existence of a non-blockable fraction of cytotoxic T lymphocytes in the spleens of MSV progressor animals (see Fig. 5 ) and the decreased ability of cytotoxic spleen cells of MSV regressor animals to be blocked (Table III) , it is tempting to speculate that non-blockable T cells are in some way responsible for tumour regression.
As a final test of the physiological relevance of this in vitro demonstration of blocking of cytotoxic lymphocytes, we investigated the effect of overnight incubation in DF10 followed by similar incubation in blocking sera on the cytotoxic potential of spleen cells taken from mice at different times post MSV inoculation. The rationale behind this approach was as follows: (1) The kinetics of development of cytotoxic cells (see Fig. 1 ) suggested that some in vivo blocking of effector cells may be taking place late in tumour progression (days 15-18); (2) earlier reports (de Landazuri and Herberman, 1972; Gorczynski and Tigelaar, 1975) had suggested that in vivo blocked cells in different tumour systems become activated for cytotoxicity after overnight incubation.
Spleen cells were pooled aseptically from groups of 5 mice inoculated with MSV at different times and aliquots of each pool were tested at different ratios for their cytotoxicity with 5 x 104 51Cr-SDLC target cells. The remainder (6 x 108) of the cells were incubated for effector: target cells needed to produce 25% specific 51Cr release with each pool of cells, except for the anti-Br-6 treated cells, where the cytotoxicity seen at that ratio of untreated cells giving 25% specific release is shown.
Comparison of the columns of Table IV reveals some interesting features. Cytotoxic activities from all pools of cells tested were increased by incubation in DF10, as indicated by the lower effector: target cell ratio needed to produce the same degree of lysis. After the incubation, the cytotoxicity remained wholly due to cytotoxic T lymphocytes. The possibility that small increases in cytotoxic potential might be explained by selective survival of cytotoxic cells (since viable cell recovery was only 55 i 10%) must be borne in mind (see also Gorczynski and Tigelaar, 1975 
DISCUSSION
The main emphasis of this work has been to analyse the ability of MSV tumour associated antigens (TAA) to block the direct cell mediated cytotoxicity significance of this phenomenon. Our initial studies suggested that the effector cells in the cytotoxic assay we employed (a 15 h 51Cr release assay) were antigen specific cytotoxic T cells. This was so irrespective of the time post MSV infec- tion at which spleen cells (containing effector cells) were harvested from immune mice (Table I and Fig. 2 ). These results concur with the studies of Herberman et al. (1973) who studied immunity to MSV in C57B1 mice, and with those of Leclerc et al. (1973) , both of whom used a similar 5'Cr release assay. They do not agree, however, with the results of Lamon et al. (1972 Lamon et al. ( , 1973 who found in the MCA evidence for a non-T cytotoxic cell at late times post MSV. However, these discrepancies may be related to the type of assay used for studying CMC, the surface antigens expressed by the target cells used and the length of the assay. As defined by velocity sedimentation (Fig. 3) , tumour cell specificity (Fig. 2) and the effects of an anti-T (rabbit anti-Br-0) or anti-B (rabbit anti-mouse immunoglobulin) antiserum (Table I ) the effector cells in the 51Cr release assay correspond well with those defined in other tests of CMI in the MSV system (Gorczynski, 1 974a). Moreover, when purified virally induced TAA were tested for their ability to inhibit cytotoxicity, the results substantially confirmed earlier data on blocking in other tests of CMI (Gorczynski et al., 1974b) and the relative importance of defined virally induced TAA in in vivo tumour rejection (see Table II and Knight and Gorezynski, 1975) . For example, the cell extract, C-Vgs, was both the most potent inhibitor of CMC and the most effective antigen for sensitizing cells capable, on adoptive transfer, of protecting sublethally irradiated mice against MSV tumour challenge .
Similarly, the viral group specific antigen, p30, inhibited CMC, stimulated blast transformation by regressor T Jymphocytes and sensitized cells which, on transfer, protected against MSV tumour challenge in vivo. Cell extracts prepared from tumour induced by several strains of MLV have also been shown to inhibit MSV-M immune CMC in a MCA (Plata and Levy, 1974) .
The data of Fig. 4 , using spleen cells from mice sensitized to both MSV-TAA and to murine alloantigens, indicate that the blocking mediated by soluble TAA (C-Vgs) or serum (20-day post MSV serum see Table II ) was antigen specific. In Table II and elsewhere we found that the serum mediated inhibition was in part due to material not absorbed on an anti-MIg column (free TAA?) and in part to material absorbed to the column. Far greater blocking was seen when these two components were mixed, however, suggesting that the most potent blockade was mediated by antigen-antibody complexes in antigen excess.
When comparing these data with the in vivo growth pattern of the tumour, several anomalies become apparent. Firstly, cytotoxicity measured by the CRT by spleen cells from tumour bearing mice (Days 11-15) was greater than from late progressors or early regressors (see Fig. 1 ). This correlates well with the development of serum blocking factors (Fig. 4) but not with tumour growth. Secondly, in earlier studies (Gorczynski, 1974c) we described how the CMI (measured by lymphocyte transformation or macrophage migration inhibition) decreased during the growth phrase of the tumour, a decrease associated with the development of a suppressor cell population (see also Kirchner et al., 1974; Kilburn et al., 1974) . Yet this was not the case with CMI measured by 51Cr release (Fig. 1) , nor were factors (antigenantibody complexes?) released by these suppressor cells which could block CMI in a 51Cr assay, though such factors were released to block other assays of CMI .
To clarify the relationship between in vivo tumour growth and in vitro CMI, we tested the effect of antigen and 20-day immune serum on fractions of spleen cells prepared by velocity sedimentation, from mice injected with MSV at one specific time and on unfractionated spleen cells from mice injected with MSV at different times. We also investigated the effect of incubating immune cells in medium before assay and the effect of antigen and 20-day immune serum on these in vitro activated cells.
The data from these experiments are detailed in Tables III and IV and Fig. 5 . In brief, we found that all unfractionated spleen cells tested showed a similar response (in terms of facility to be blocked) to soluble MSV-TAA (C-Vgs), but a widely different response to serum blocking factors. In particular, spleen cells showed a marked decline in their ability to be blocked at around the time of tumour regression, and the decrease was maintained in regressor animals (Table III) . When spleen cells from MSV progressor animals were fractionated, a population of cells was identified which was refractory to blocking by C-Vgs and serum. It is interesting to note that this pool of cytotoxic non-blockable T cells co-sediments with the suppressor cells earlier described (Gorczynski, 1974c) . This may help to explain why suppressor cells and their soluble products had no effect on CMI analysed by a 5'Cr test. Finally, as described by de Landazuri and Herberman (1972) for a rat lymphoma, we found that Balb/c MSV regressor animals contained spleen cells whose cytotoxic potential was markedly increased by overnight incubation in medium. However, and equally interesting, the same was also true of MSV late progressor and early regressor animals (Table IV) . Again, as determined by treatment with anti-Br-0, the cytotoxic cells after overnight incubation were T lymphocytes (see Table IV ). The increase in cytotoxic activity after incubation in vitro could be abolished if the cells were now reincubated in blocking serum (Table IV) .
Although, therefore, the cytotoxicity of unfractionated immune spleen cells taken between 10 and 30 days after MSV injection can be inhibited by antigen and by 20-day serum, a subpopulation can be fractionated by velocity sedimentation which is cytotoxic, but which is refractory to inhibition by these reagents. These non-inhibitable lymphocytes may indeed be the subpopulation most relevant to the tumour status of the animal, particularly from the time when the animal's serum becomes inhibitory to other cytotoxic cells. Since this cell population co-sediments with non-T cells which suppress other parameters of CMI (Gorczynski, 1974c) , however, the suppressor cell product, rather than inhibiting direct cytotoxicity, may bind to the cytotoxic T cell surface so as to prevent the binding of antigen or blocking serum. There is evidence, however, that suppressor cells can reduce the protective effect of MSV regressor T lymphocytes adoptively transferred to sublethally irradiated mice (Gorczynski and Norbury, 1974) .
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